Literature DB >> 23986355

Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).

Stefano Partelli1, Sebastien Gaujoux, Letizia Boninsegna, Rim Cherif, Stefano Crippa, Anne Couvelard, Aldo Scarpa, Philippe Ruszniewski, Alain Sauvanet, Massimo Falconi.   

Abstract

IMPORTANCE: Nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) are often indolent neoplasms without lymph node (LN) metastasis at diagnosis. Therefore, in patients with low risk of LN metastasis, the extent of surgery and lymphadenectomy could be limited and follow-up adjusted to the very low risk of relapse.
OBJECTIVE: To construct a predicting model to assess the risk of pN+ prior to surgical resection for NF-PanNETs using preoperative retrievable variables.
DESIGN: Retrospective review using multiple logistic regression analysis to construct predictive model of pN+ based on preoperatively available data.
SETTING: The combined prospective databases of the Surgical Departments of the University of Verona, Verona, Italy, and Beaujon Hospital, Clichy, France, were queried for clinical and pathological data. PARTICIPANTS: All patients with resected (R0 or R1), pathologically confirmed NF-PanNETs between January 1, 1993 and December 31, 2009. MAIN OUTCOME AND MEASURE: Risk of lymph node metastases in patients with pancreatic neuroendocrine tumors.
RESULTS: Among 181 patients, nodal metastases were reported in 55 patients (30%) and were associated with decreased 5-year disease-free survival (70% vs 97%, P < .001). Multivariable analysis showed that independent factors associated with nodal metastasis were radiological nodal status (rN) (odds ratio [OR], 5.58; P < .001) and tumor grade (NET-G2 vs NET-G1: OR, 4.87; P < .001) (first model). When the tumor grade was excluded, rN (OR, 4.73; P = .001) and radiological tumor size larger than 4 cm (OR, 2.67; P = .03) were independent predictors of nodal metastasis (second model). The area under the receiver operating characteristic curve for the first and second models were 80% and 74%, respectively. CONCLUSIONS AND RELEVANCE: Patients with NF-PanNET-G1 have a very low risk of pN+ in the absence of radiological signs of node involvement. When preoperative grading assessment is not achieved, the radiological size of the lesion is a powerful alternative predictor of pN+. The risk of pathological nodal involvement in patients with NF-PanNETs can be accurately estimated by a clinical predictive model.

Entities:  

Mesh:

Year:  2013        PMID: 23986355     DOI: 10.1001/jamasurg.2013.3376

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  38 in total

Review 1.  Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach.

Authors:  Tomoki Shirota; Yuichi Nagakawa; Yatsuka Sahara; Chie Takishita; Yosuke Hijikata; Yuichi Hosokawa; Tetsushi Nakajima; Hiroaki Osakabe; Kenji Katsumata; Akihiko Tsuchida
Journal:  Gland Surg       Date:  2018-02

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

3.  A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique.

Authors:  Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; Maria C Russell; Kenneth Cardona; Patrick S Sullivan; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2019-08-26       Impact factor: 3.454

4.  Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Authors:  Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2020-02-05       Impact factor: 3.452

5.  Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Authors:  Hussein A Assi; Sarbajit Mukherjee; Pamela L Kunz; Michael Machiorlatti; Sara Vesely; Vipul Pareek; Hassan Hatoum
Journal:  Oncologist       Date:  2019-10-02

6.  A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.

Authors:  Mohammad Y Zaidi; Alexandra G Lopez-Aguiar; Jeffrey M Switchenko; Joseph Lipscomb; Valentina Andreasi; Stefano Partelli; Adriana C Gamboa; Rachel M Lee; George A Poultsides; Mary Dillhoff; Flavio G Rocha; Kamran Idrees; Clifford S Cho; Sharon M Weber; Ryan C Fields; Charles A Staley; Massimo Falconi; Shishir K Maithel
Journal:  Ann Surg       Date:  2019-09       Impact factor: 12.969

Review 7.  State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Authors:  Eric P Tamm; Priya Bhosale; Jeffrey H Lee; Eric M Rohren
Journal:  Surg Oncol Clin N Am       Date:  2016-04       Impact factor: 3.495

Review 8.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

9.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

10.  Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Authors:  L Bodei; M Kidd; I M Modlin; S Severi; I Drozdov; S Nicolini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.